MedTrace Logo

Vitamin D and Zinc Supplementation for Improving Treatment Outcomes Among COVID-19 Patients in India

NCT04641195 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 181

Last updated 2022-09-19

No results posted yet for this study

Summary

The purpose of this study is to assess the effect of vitamin D and/or zinc supplementation on improving COVID-19 treatment outcomes. The effects of vitamin D, zinc, and both vitamin D and zinc together will be investigated among COVID-19 patients in India.

Conditions

Interventions

DIETARY_SUPPLEMENT

Vitamin D3 (cholecalciferol)

180,000 international units (IU) of vitamin D3 at enrollment, followed by 2000 IU once per day from enrollment to 8 weeks

DIETARY_SUPPLEMENT

Zinc (zinc gluconate)

40mg of zinc gluconate taken once per day from enrollment to 8 weeks

DIETARY_SUPPLEMENT

Zinc (zinc gluconate) & Vitamin D (cholecalciferol)

180,000 IU of vitamin D3 at enrollment, followed by 2000 IU of vitamin D3 and 40mg of zinc gluconate once per day from enrollment to 8 weeks

OTHER

Placebo

Placebo vitamin D bolus at enrollment followed by placebo daily vitamin D maintenance doses and placebo daily zinc supplements.

Sponsors & Collaborators

  • Foundation for Medical Research

    collaborator OTHER

  • University Health Network, Toronto

    collaborator OTHER

  • Harvard School of Public Health (HSPH)

    lead OTHER

Principal Investigators

  • Wafaie W Wafaie, MBBS, MPH, MS, DrPH · Harvard School of Public Health (HSPH)

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
FACTORIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-04-22
Primary Completion
2022-07-01
Completion
2022-08-01

Countries

  • India

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04641195 on ClinicalTrials.gov